Bullfrog AI Holdings, Inc. Stock Price, News & Analysis

BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) announced a strategic partnership with the Sage Group to advance its Phase 2 ready oncology asset targeting glioblastoma, a deadly brain cancer, along with a preclinical prodrug asset. The partnership will leverage Sage Group's clinical and regulatory expertise to identify joint venture opportunities for global clinical development.

The glioblastoma treatment market is projected to exceed $10 billion by 2030, growing from $5.1 billion in 2020, highlighting significant market potential. BullFrog AI has exclusive licenses from Johns Hopkins University for innovative formulations of mebendazole, which have undergone clinical trials, aiming to provide new treatment options for patients.

BullFrog AI Holdings (Nasdaq: BFRG) announced an exclusive license agreement with Johns Hopkins University for prodrug compositions of mebendazole, signed on October 13, 2022. This world-wide, royalty-bearing license allows BullFrog to commercialize N-substituted prodrugs that improve solubility and bioavailability compared to the original compound. The prodrugs target oncology treatments, notably glioblastoma, leveraging BullFrog's AI technology to enhance drug development efficiency. Vin Singh, the CEO, emphasized the potential of this asset in their oncology pipeline. BullFrog AI is committed to advancing precision medicine through machine learning in drug development, aiming to reduce costs and improve patient outcomes.

GAITHERSBURG, Md., April 13, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, a digital technology company focused on precision medicine, announced CEO Vin Singh's participation in a panel at the Money Show in Las Vegas on April 24-26, 2023. The panel, titled 'Innovators in a Dynamic Tech Environment - A Perfect Fit for Your Portfolio,' will occur at 3:10 p.m. PT on April 24 and 1:15 p.m. PT on April 25.

Singh plans to discuss the company's vision and how its machine learning technology enhances drug development. Following its recent Nasdaq IPO, BullFrog AI aims to accelerate progress in the coming quarters. The Money Show connects investors with financial experts, providing insights and strategies.

For more details, visit the company's website.

On April 6, 2023, BullFrog AI Holdings, Inc. (Nasdaq: BFRG; BFRGW) announced that CEO Vin Singh will appear on The RedChip Money Report on Bloomberg TV on April 8, 2023, at 7 p.m. ET. The broadcast reaches approximately 73 million homes in the U.S. Singh will discuss the company’s exclusive licensing agreement with Johns Hopkins’ Applied Physics Lab for its AI technology in drug development, the current development pipeline, and potential partnership opportunities.

BullFrog AI specializes in precision medicine using machine learning. Its proprietary bfLEAP™ platform aims to enhance drug development success by predicting patient responses, ultimately reducing development costs and improving patient outcomes.

BullFrog AI Holdings (Nasdaq: BFRG; BFRGW) has announced a worldwide license agreement with Johns Hopkins University Applied Physics Laboratory for patented technology to enhance its bfLEAP™ platform, which focuses on accelerating therapeutic development. This platform employs advanced analytics to improve the identification of relevant data, thereby potentially reducing development costs and failure rates for new therapeutics. The licensed technologies include Prometheus and Seagull, which enhance data analysis capabilities. BullFrog aims to use this technology to streamline drug development and improve patient outcomes.

BullFrog AI Holdings (NASDAQ: BFRG; BFRGW) has announced its listing on the Webull platform, connecting with over 1.3 million active investors. This collaboration aims to enhance communication with shareholders by providing real-time updates on corporate activities such as news, earnings, and presentations. Founder and CEO Vin Singh expressed excitement about the partnership, emphasizing the efficiency of digital communications for reaching investors. BullFrog AI focuses on precision medicine and AI-driven drug development, using its proprietary bfLEAP™ platform to optimize therapeutic outcomes and reduce costs in pharmaceutical development.

BullFrog AI Holdings (NASDAQ:BFRG; BFRGW) has announced a collaboration with the J. Craig Venter Institute to co-develop a synthetic HSV-1 virus targeting colorectal cancer. This partnership aims to utilize BullFrog's bfLEAP™ AI platform for optimizing cancer therapeutics with reduced toxicity while enhancing efficacy. With colorectal cancer being the third most prevalent cancer in the U.S., this project seeks to create a novel class of treatments, potentially revolutionizing precision medicine. The initiative emphasizes BullFrog's commitment to advancing drug development through AI innovation.

On February 16, 2023, Bullfrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) successfully completed its IPO, raising approximately $8.4 million by selling 1,297,318 units at $6.50 per unit. Each unit comprises one share of common stock and two types of warrants. The offering includes an underwriters' option to purchase additional shares, amounting to 15% of the units sold, within 45 days. This capital will support Bullfrog AI's mission to advance precision medicine through machine learning technologies. WallachBeth Capital and Kingswood served as the joint bookrunners for this offering.

Bullfrog AI Holdings (NASDAQ:BFRG; BFRGW) has successfully closed its initial public offering, securing approximately $8.4 million through the sale of 1,297,318 units priced at $6.50 each. Each unit includes one share of common stock and two warrants with exercise prices of $7.80 and $8.125. Trading for the shares and tradeable warrants commenced on February 14, 2023. The underwriters hold an option to purchase up to 15% additional shares within 45 days. Bullfrog AI focuses on using machine learning for precision medicine, partnering with major institutions like Johns Hopkins University to enhance drug development.